ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 218 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2021. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,417,427 | -27.0% | 211,241 | -3.9% | 0.01% | +20.0% |
| Q1 2023 | $1,940,728 | +60.5% | 219,788 | +38.9% | 0.01% | -37.5% |
| Q4 2022 | $1,209,144 | +7.1% | 158,265 | -0.2% | 0.01% | -42.9% |
| Q3 2022 | $1,129,000 | +72.1% | 158,584 | +95.4% | 0.01% | +100.0% |
| Q2 2022 | $656,000 | -39.4% | 81,157 | +4.1% | 0.01% | -58.8% |
| Q1 2022 | $1,082,000 | -26.4% | 77,934 | +48.7% | 0.02% | -22.7% |
| Q4 2021 | $1,470,000 | -40.0% | 52,400 | -27.3% | 0.02% | -59.3% |
| Q3 2021 | $2,450,000 | -11.0% | 72,084 | +7.0% | 0.05% | -10.0% |
| Q2 2021 | $2,752,000 | +20.3% | 67,353 | +18.5% | 0.06% | +11.1% |
| Q1 2021 | $2,288,000 | -13.6% | 56,826 | +26.9% | 0.05% | -36.5% |
| Q4 2020 | $2,647,000 | +21.1% | 44,772 | -0.4% | 0.08% | -5.6% |
| Q3 2020 | $2,185,000 | +845.9% | 44,939 | +839.6% | 0.09% | +592.3% |
| Q2 2020 | $231,000 | – | 4,783 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |